Viewing nowCombinationGlimemajac Tablet 50/1000 mg (Sitagliptin, Metformin)
Metformin Hydrochloride 1000mg · Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication · Combination
McNealty Pharmaceuticals Co., Ltd.

MFDS item code 202301975 · Approved 2023.06.27 · Insurance code 641502990
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps control blood sugar levels in patients with type 2 diabetes by combining the effects of sitagliptin and metformin. It provides additional blood sugar management effects for patients who are also following dietary and exercise regimens. This helps maintain blood sugar levels more stably, supporting diabetes management. Therefore, this medication is used for improving blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Contraindications). 2. Patients receiving metformin treatment: - For patients whose glycemic control is inadequate with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose glycemic control is inadequate with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or eGFR ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication contains two ingredients that help control blood sugar levels. First, one of this medication's components may cause allergic reactions, so if symptoms such as skin rash, hives, or severe cases such as breathing difficulties occur, it is essential to stop taking the medication immediately and consult a physician. Additionally, this component has been reported to potentially cause a serious side effect known as pancreatitis, characterized by inflammation of the pancreas; therefore, if symptoms like abdominal pain or vomiting occur during use, careful observation is required and discontinuation may be necessary. The other component should not be administered to patients with weakened kidney function or those in states that could affect kidney function, such as dehydration, severe infections, heart failure, or acute myocardial infarction. Furthermore, this medication is not recommended for pregnant women, women who may become pregnant, lactating women, or children under 18 years old. During the use of this medication, kidney function should be regularly monitored, and if kidney function declines, the medication should be discontinued. This medication may cause hypoglycemia; therefore, especially when taken with other blood sugar-lowering medications, it is important to frequently check blood sugar levels and be alert for symptoms of hypoglycemia. Additionally, a rare but serious metabolic disorder known as lactic acidosis may occur, so if sudden fatigue, muscle pain, difficulty breathing, or abdominal pain manifests, it is crucial to notify a physician immediately. It is advisable to avoid alcohol consumption while taking this medication, and if a surgery is approaching or tests using iodinated contrast agents are planned, temporary discontinuation of the medication should be considered. Maintaining regular meals and appropriate exercise is important during medication use, and any abnormal symptoms should be reported to healthcare professionals promptly. Lastly, this medication may interact with certain other drugs, so if other medications are being taken concurrently, it is essential to inform healthcare professionals.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air exposure and kept at room temperature between 1 and 30 degrees Celsius. This storage condition helps maintain the effectiveness of the medication.
Brown oval film-coated tablet
60 tablets/box [10 tablets/PTP x 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication · Combination
McNealty Pharmaceuticals Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.